A Phase 3 interventional study of FEC Chemotherapy and Surgery in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-22.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 25th largest by enrollment, is one of 6 that started in 2016, is one of 23 in phase 3, and was the 39th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 329 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 50th largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2016, is one of 61 in phase 3, and was the 156th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve participants with early-stage or locally advanced HER2-positive breast cancer. The anticipated treatment duration is approximately 17 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
Drug: FEC Chemotherapy · Procedure: Surgery · Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab
Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
Drug: FEC Chemotherapy · Procedure: Surgery · Drug: Docetaxel · Drug: Placebo · Drug: Trastuzumab
Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
Also known as: RO4368451
Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
Also known as: RO0452317
Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)
This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Percentage of Participants With tpCR as Assessed by the Local Pathologist
This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC
This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Percentage of Participants With bpCR as Assessed by the Local Pathologist
This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1
An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 \& 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year \& then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive \& event-free.
Time frame: From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.
Time frame: From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.
Time frame: From Baseline to OS event or date last known to be alive at 1, 3, and 5 years
Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period
The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.
Time frame: Baseline up to end of Cycle 4 (1 cycle = 21 days)
Percentage of Participants With at Least One AE During the Adjuvant Treatment Period
Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
Time frame: From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year)
Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period
The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.
Time frame: From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years)
Percentage of Participants Who Experienced a Primary Cardiac Event
A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.
Time frame: From Baseline until end of study (up to 6 years)
Percentage of Participants Who Experienced a Secondary Cardiac Event
A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.
Time frame: From Baseline until end of study (up to 6 years)
Maximum Change From Baseline in LVEF
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.
Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
Change From Baseline in LVEF Over Time
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.
Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
A total of 329 participants with early-stage or locally advanced human epidermal growth factor receptor (HER) 2-positive breast cancer were enrolled in this study at 23 investigative sites in China, Republic of Korea, Taiwan, and Thailand from 14 March 2016 to 14 March 2022.
| Milestone | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Started | 219 | 110 |
| Received at least one dose of study treatment | 218 | 110 |
| Completed neoadjuvant treatment | 214 | 108 |
| Underwent surgery | 210 | 105 |
| Completed | 208 | 103 |
| Not completed | 11 | 7 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Progression of disease | 2 | 3 |
| Withdrew: Did not receive study drug | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 2 | 1 |
| Milestone | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Started | 208 | 103 |
| Started adjuvant fec treatment | 208 | 103 |
| Started adjuvant anti-her2 treatment | 204 | 99 |
| Completed | 198 | 94 |
| Not completed | 10 | 9 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Recurrent disease | 4 | 5 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Milestone | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Started | 208 | 104 |
| Completed | 175 | 82 |
| Not completed | 33 | 22 |
| Withdrew: Death | 11 | 11 |
| Withdrew: Lost to follow-up | 9 | 4 |
| Withdrew: Withdrawal by subject | 13 | 3 |
| Withdrew: Non-compliance | 0 | 1 |
| Withdrew: Reason not specified | 0 | 3 |
This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) | 39.3 (32.76 to 46.08) | 21.8 (14.51 to 30.70) |
This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With tpCR as Assessed by the Local Pathologist | 39.3 (32.76 to 46.08) | 20.9 (13.74 to 29.70) |
This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC | 42.0 (35.39 to 48.85) | 23.6 (16.06 to 32.68) |
This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With bpCR as Assessed by the Local Pathologist | 41.6 (34.95 to 48.39) | 22.7 (15.28 to 31.70) |
Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Complete Response | 11.0 (7.15 to 15.87) | 10.0 (5.10 to 17.19) |
| Partial Response | 77.6 (71.52 to 82.97) | 68.2 (58.62 to 76.74) |
| Stable Disease | 8.2 (4.94 to 12.68) | 19.1 (12.22 to 27.69) |
| Progressive Disease | 0.5 (0.01 to 2.52) | 1.8 (0.22 to 6.41) |
| Missing or Unevaluable | 2.7 (NA to NA) | 0.9 (NA to NA) |
An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1 | 88.6 (83.61 to 92.47) | 78.2 (69.30 to 85.49) |
Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 \& 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year \& then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive \& event-free.
| estimate of percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| 1 Year | 98.62 (97.06 to 100.00) | 90.46 (84.82 to 96.09) |
| 3 Years | 88.85 (84.55 to 93.15) | 79.68 (71.91 to 87.45) |
| 5 Years | 84.80 (79.86 to 89.73) | 73.70 (65.17 to 82.23) |
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.
| estimate of percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| 1 Year | 97.55 (95.42 to 99.67) | 92.08 (86.81 to 97.35) |
| 3 Years | 90.09 (85.97 to 94.22) | 81.10 (73.44 to 88.75) |
| 5 Years | 85.99 (81.17 to 90.80) | 75.02 (66.53 to 83.51) |
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.
| estimate of percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| 1 Year | 99.54 (98.64 to 100.00) | 100.00 (100.00 to 100.00) |
| 3 Years | 97.01 (94.64 to 99.37) | 90.99 (85.37 to 96.60) |
| 5 Years | 93.86 (90.49 to 97.23) | 89.97 (84.06 to 95.87) |
The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period | 97.7 | 96.4 |
Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With at Least One AE During the Adjuvant Treatment Period | 98.1 | 98.1 |
The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period | 6.0 | 7.3 |
A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants Who Experienced a Primary Cardiac Event | 0 | 0 |
A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.
| percentage of participants | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Percentage of Participants Who Experienced a Secondary Cardiac Event | 0 | 0 |
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.
| percentage points of LVEF | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Maximum Change From Baseline in LVEF | -6.55 ± 5.22 | -6.20 ± 6.08 |
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.
| percentage points of LVEF | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Cycle 2 Day 1 | -0.62 (-1.35 to 0.11) | 0.29 (-0.89 to 1.46) |
| Cycle 4 Day 1 | -1.02 (-1.72 to -0.32) | 0.09 (-1.03 to 1.22) |
| Cycle 5 Day 1 | -0.96 (-1.70 to -0.22) | 0.07 (-1.12 to 1.26) |
| Cycle 8 Day 1 | -1.63 (-2.44 to -0.81) | -1.18 (-2.30 to -0.05) |
| Cycle 11 Day 1 | -1.38 (-2.16 to -0.61) | -0.65 (-1.91 to 0.62) |
| Cycle 20 Day 1 | -1.22 (-2.05 to -0.38) | -1.18 (-2.56 to 0.20) |
Collected over From first dose of any study drug through end of study (up to 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | 12/218 (5.5%) | 37/218 (17%) | 218/218 (100%) |
| Placebo, Trastuzumab, and Chemotherapy | 11/110 (10%) | 15/110 (13.6%) | 108/110 (98.2%) |
| Event | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 9/218 | 3/110 |
| PneumoniaInfections and infestations | 4/218 | 1/110 |
| MyelosuppressionBlood and lymphatic system disorders | 3/218 | 0/110 |
| DiarrhoeaGastrointestinal disorders | 2/218 | 0/110 |
| VomitingGastrointestinal disorders | 2/218 | 0/110 |
| Liver DisorderHepatobiliary disorders | 2/218 | 0/110 |
| BacteraemiaInfections and infestations | 2/218 | 0/110 |
| Urinary Tract InfectionInfections and infestations | 2/218 | 1/110 |
| AnaemiaBlood and lymphatic system disorders | 1/218 | 1/110 |
| Blood Loss AnaemiaBlood and lymphatic system disorders | 0/218 | 1/110 |
| Event | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 153/218 | 73/110 |
| LeukopeniaBlood and lymphatic system disorders | 135/218 | 67/110 |
| AlopeciaSkin and subcutaneous tissue disorders | 115/218 | 56/110 |
| DiarrhoeaGastrointestinal disorders | 87/218 | 19/110 |
| NauseaGastrointestinal disorders | 84/218 | 40/110 |
| Alanine Aminotransferase IncreasedInvestigations | 64/218 | 41/110 |
| AnaemiaBlood and lymphatic system disorders | 75/218 | 36/110 |
| Aspartate Aminotransferase IncreasedInvestigations | 54/218 | 34/110 |
| Upper Respiratory Tract InfectionInfections and infestations | 58/218 | 14/110 |
| RashSkin and subcutaneous tissue disorders | 28/218 | 22/110 |
Intent-to-Treat (ITT) population included all participants who were enrolled regardless of whether they received any study treatment.
| Age, Continuous(years) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Mean | 48.4 ± 9.7 | 49.5 ± 9.1 | 48.8 ± 9.5 |
| Age, Customized(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| <40 years old | 40 | 18 | 58 |
| 40-49 years old | 75 | 40 | 115 |
| 50-64 years old | 96 | 44 | 140 |
| ≥65 years old | 8 | 8 | 16 |
| Sex: Female, Male(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Female | 219 | 110 | 329 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 219 | 110 | 329 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 219 | 110 | 329 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Disease Category(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Early Stage | 152 | 77 | 229 |
| Locally Advanced | 67 | 33 | 100 |
| Hormone Receptor Status(Participants) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Estrogen Receptor (ER) and Progesterone Receptor (PgR) Negative | 105 | 54 | 159 |
| Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Positive | 114 | 56 | 170 |
| Baseline LVEF value(percentage points of LVEF) | Pertuzumab, Trastuzumab, and Chemotherapy | Placebo, Trastuzumab, and Chemotherapy | Total |
|---|---|---|---|
| Mean | 66.41 ± 4.93 | 66.03 ± 5.19 | 66.28 ± 5.01 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Oct 2017, 19 months.
Results were first posted in Jan 2019, 1 year 2 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 19 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab